�鶹ѧ����Ʒ��

Journal Article

1. Kitamura F, Kline T, Warren D, Moy L, Daneshjou R, Maleki F, Santos I, Gichoya J, Wiggins W, Bialecki B, ODonnell K, Flanders AE, Morgan M, Safdar N, Andriole KP, Geis R, Allen B, Dreyer K, Lungren M, Wood MJ, Kohli M, Langer S, Shih G, Farina E, Kahn CE Jr, Reiser I, Giger M, Wald C, Mongan J, Cook T, Tenenholtz N (2025). Teaching AI for Radiology Applications: A Multisociety-Recommended Syllabus from the AAPM, ACR, RSNA, and SIIM. Radiol Artif Intell, 7(6), e250137. ()
2. Kitamura F, Kline T, Warren D, Moy L, Daneshjou R, Maleki F, Santos I, Gichoya J, Wiggins W, Bialecki B, ODonnell K, Flanders AE, Morgan M, Safdar N, Andriole KP, Geis R, Allen B, Dreyer K, Lungren M, Wood MJ, Kohli M, Langer S, Shih G, Farina E, Kahn CE Jr, Reiser I, Giger M, Wald C, Mongan J, Cook T, Tenenholtz N (2025). Teaching AI for Radiology Applications: A Multisociety‑Recommended Syllabus from the AAPM, ACR, RSNA, and SIIM. Med Phys, 52(10), e17779. ()
3. Tripathi A, Chen Y, Jarrard DF, Garcia JA, Dreicer R, Liu G, Hussain MH, Shevrin DH, Cooney M, Eisenberger MA, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Carducci MA, DiPaola RS, Sweeney CJ (2025). Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. Ann Oncol. ()
4. Sharifi MN, Feng E, Rydzewski NR, Taylor AK, Sperger JM, Shi Y, Helzer KT, Bootsma ML, Carreno V, Chang AH, Nunamaker LA, Blitzer GC, Shang TA, Subramanian A, Bjartell A, Josefsson A, Wikstrm P, Feng E, Kohli M, Yang R, Dehm SM, Small EJ, Aggarwal R, Quigley DA, Lang JM, Zhao SG, Sjstrm M (2025). Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer. Mol Oncol, 19(8), 2348-2365. ()
5. Sinawang PD, Multani P, Ozen MO, Wong J, Akin D, Hanson C, Larsen M, Ampaw E, Rondina MT, Tolley ND, Wang L, Cunningham BT, Kohli M, Demirci U (2025). Plasma Preparation Strategies for Extracellular Vesicle-Based Biomarkers in Metastatic Castration-Resistant Prostate Cancer. J Extracell Biol, 4(8), e70071. ()
6. Huo X, Kohli M, Finkelstein J (2025). Machine Learning Approaches for Predicting Mortality in Metastatic Castration-Resistant Prostate Cancer. Stud Health Technol Inform, 328, 26-30. ()
7. Mahadevan A, Pinnamaneni M, Doshi P, Kohli M, Krishnakumar M, Salian RB, Akella SA, Adivi S, Radhareddy AR, Desai R (2025). Prevalence, trends, and outcomes of metabolically healthy obesity or overweight in stroke hospitalizations of elderly patients: A 2016-2019 US population analysis. J Neurol Sci, 472, 123445. ()
8. Wong J, Tian Y, Patel MS, Avasthi K, Hanson C, Larsen M, Ampaw E, Fadlullah MZH, Finklestein J, Tan AC, Park J, Manley BJ, Huang CC, Kohli M, Wang L (2025). Plasma Cell-Free DNA Methylation-Based Prognosis in Metastatic Castrate-Resistant Prostate Cancer. Res Sq. ()
9. Lee H, Shen J, Fadlullah MZ, Neibling A, Hanson C, Ampaw E, Lin T, Larsen M, Lloyd J, Maughan BL, Swami U, Gupta S, Tward J, Johnson SB, ONeil B, Schmidt B, Dechet CB, Haaland B, Wang L, Tan AC, Kohli M (2025). Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer. Clin Proteomics, 22(1), 13. ()
10. Huo X, Kohli M, Finkelstein J (2025). Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram. Stud Health Technol Inform, 323, 164-168. ()
11. Huo X, Kohli M, Finkelstein J (2025). Using Machine Learning to Predict Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. Stud Health Technol Inform, 323, 169-173. ()
12. Gabriel AS, Rocco P, Reategui-Rivera CM, Smiley A, Lloyd J, Kohli M, Finkelstein J (2025). Patient Perceptions of Virtual Reality in Cancer Rehabilitation: A Qualitative Study. Stud Health Technol Inform, 323, 399-403. ()
13. Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalainen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L (2025). 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies. Commun Med (Lond), 5(1), 61. ()
14. Fadlullah MZH, Nix D, Herberts C, Maurice-Dror C, Wyatt AW, Schmidt B, Fairbourn B, Tan AC, Wang L, Kohli M (2024). Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer. JNCI Cancer Spectr, 9(2). ()
15. Lakritz S, Nicklawsky A, Alami V, Kohli M, Moskaluk C, Riedlinger G, Salhia B, Singer EA, Naqash AR, Nepple K, Edge S, Myint Z, Kolesar J, Adra N, Flaig T, Graham LS (2024). Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations. Clin Genitourin Cancer, 23(1), 102293. ()
16. Jo Y, Chipman JJ, Haaland B, Greene T, Kohli M (2024). Multigene Copy Number Alteration Risk Score Biomarker-Based Enrichment Study Designs in Metastatic Castrate-Resistant Prostate Cancer. JCO Precis Oncol, 8, e2400399. ()
17. Gabriel AS, Rocco P, Reategui-Rivera CM, Smiley A, Lloyd J, Kohli M, Finkelstein J (2024). Qualitative Assessment of Attitudes Towards Telerehabilitation in Patients with Metastatic Prostate Cancer. Stud Health Technol Inform, 321, 104-108. ()
18. Liu W, Ayupova T, Wang W, Shepherd S, Wang X, Akin LD, Kohli M, Demirci U, Cunningham BT (2024). Dynamic and large field of view photonic resonator absorption microscopy for ultrasensitive digital resolution detection of nucleic acid and protein biomarkers. Biosens Bioelectron, 264, 116643. ()
19. Dindinger-Hill K, Hu S, Hickman A, Choudry M, Vehawn J, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Kohli M, ONeil B, Schmidt B, Dechet C, Hashibe M, Sanchez A (2024). Association of Baseline Pre-Diagnosis and Post-Diagnosis Obesity and Weight Change with Cardiovascular Risk and Survival Among Nonmetastatic Prostate Cancer Survivors. Clin Genitourin Cancer, 22(3), 102057. ()
20. Sahu KK, Li H, Mathew Thomas V, Benson M, Boucher K, Gupta S, Kohli M, Swami U, Agarwal N, Maughan BL (2023). A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR). Oncologist, 29(5), 450-e725. ()
21. Coletta AM, Simon LH, Maslana K, Taylor S, Larson K, Hansen PA, Thomas VM, Ulrich CM, Kohli M, Chipman J, Swami U, Gupta S, Maughan BL, Agarwal N (2024). Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial. BMC Cancer, 24(1), 493. ()
22. Whitworth P, Vicini F, Valente SA, Brownson K, DuPree B, Kohli M, Lawson L, Shah C (2022). Reducing rates of chronic breast cancer-related lymphedema with screening and early intervention: an update of recent data. J Cancer Surviv, 18(2), 344-351. ()
23. Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Mathew Thomas V, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL (2023). Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors. Urol Pract, 11(1), 32-35. ()
24. Dutta S, Bhattacharya S, Harris H, Islam R, Bodas S, Polavaram N, Mishra J, Das D, Seshacharyulu P, Kalluchi A, Pal A, Kohli M, Lele S, Muders M, Batra S, Ghosh P, Datta K, Rowley M (2023). Understanding the role of Pax5 in development of taxane-resistant neuroendocrine like prostate cancers. Res Sq. ()
25. Yoo M, Nelson RE, Haaland B, Dougherty M, Cutshall ZA, Kohli R, Beckstead R, Kohli M (2023). Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective. J Natl Cancer Inst, 115(11), 1374-1382. ()
26. Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL (2023). Reply by Authors. Urol Pract, 101097UPJ000000000000047102. ()
27. Carthon BC, Kim SE, McDermott DF, Dutcher JP, Puligandla M, Manola J, Pins M, Carducci MA, Plimack ER, Appleman LJ, MacVicar GR, Kohli M, Kuzel TM, DiPaola RS, Haas NB (2023). Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808. Clin Genitourin Cancer, 21(5), 546-554. ()
28. Fettke H, Dai C, Kwan EM, Zheng T, Du P, Ng N, Bukczynska P, Docanto M, Kostos L, Foroughi S, Brown S, Graham LK, Mahon K, Horvath LG, Jia S, Kohli M, Azad AA (2023). BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype. EBioMedicine, 95, 104738. ()
29. Larson J, Ozen MO, Kohli M, Akin D, Demirci U (2023). Systematic Analysis of Tissue-Derived and Biofluid Extracellular Vesicle miRNAs Associated with Prostate Cancer. Adv Biol (Weinh), 7(7), e2200327. ()
30. Fang S, Zhe S, Lin HM, Azad AA, Fettke H, Kwan EM, Horvath L, Mak B, Zheng T, Du P, Jia S, Kirby RM, Kohli M (2023). Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer. JCO Clin Cancer Inform, 7, e2300057. ()
31. Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM Jr, Quinn DI (2022). Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin Oncol, 40(28), 3301-3309. ()
32. Tan W, Zheng T, Wang A, Roacho J, Thao S, Du P, Jia S, Yu J, King BL, Kohli M (2022). Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer. Sci Rep, 12(1), 4672. ()
33. Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal N (2021). Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist, 26(12), 1006-e2129. ()
34. Che M, Chaturvedi A, Munro SA, Pitzen SP, Ling A, Zhang W, Mentzer J, Ku SY, Puca L, Zhu Y, Bergman AM, Severson TM, Forster C, Liu Y, Hildebrand J, Daniel M, Wang TY, Selth LA, Hickey T, Zoubeidi A, Gleave M, Bareja R, Sboner A, Tilley W, Carroll JS, Tan W, Kohli M, Yang R, Hsieh AC, Murugan P, Zwart W, Beltran H, Huang RS, Dehm SM (2021). Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nat Commun, 12(1), 6377. ()

Review

1. Shah C, Whitworth P, Valente S, Schwarz GS, Kruse M, Kohli M, Brownson K, Lawson L, Dupree B, Vicini FA (2022). Bioimpedance spectroscopy for breast cancer-related lymphedema assessment: clinical practice guidelines. [Review]. Breast Cancer Res Treat, 198(1), 1-9. ()

Editorial

1. Kohli M (2023). Cancer Prescriptions and Impact on Climate Change: Real or Imagined? JCO Oncol Pract, 19(9), 697-699. ()

Newspaper

1. Kitamura F, Kline T, Warren D, Moy L, Daneshjou R, Maleki F, Santos I, Gichoya J, Wiggins W, Bialecki B, ODonnell K, Flanders AE, Morgan M, Safdar N, Andriole KP, Geis R, Allen B, Dreyer K, Lungren M, Wood MJ, Kohli M, Langer S, Shih G, Farina E, Kahn CE Jr, Reiser I, Giger M, Wald C, Mongan J, Cook T, Tenenholtz N (2025). Teaching AI for Radiology Applications: a Multisociety-Recommended Syllabus from the AAPM, ACR, RSNA, and SIIM. J Imaging Inform Med. ()

Huntsman Cancer Institute News

• Fueling Discovery: New Endowed Chairs
• How Virtual Reality Could Transform Prostate Cancer Rehabilitation
• Advancing Individualized Treatment for Metastatic Prostate Cancers
• Working to Reduce Cancer Health Disparities in the Mountain West